For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Sufentanil - Pain
PAD Profile : Sufentanil - Pain
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Oxycodone
- Co-codamol (Codeine phosphate/paracetamol)
- Tramadol hydrochloride
- Oxycodone hydrochloride/naloxone hydrochloride
- Fentanyl
- Tramadol hydrochloride
- Tramadol hydrochloride
- Paracetamol
- Codeine phosphate
- Dihydrocodeine tartrate
- Buprenorphine
- Morphine sulfate
- Pregabalin
- Gabapentin
- Dronabinol/cannabidiol
- Co-dydramol (Dihydrocodeine/paracetamol)
- Ibuprofen
- Meptazinol hydrochloride
- Pethidine hydrochloride
- Diamorphine hydrochloride
- Alfentanil hydrochloride
- Co-dydramol (Dihydrocodeine/paracetamol)
- Co-dydramol (Dihydrocodeine/paracetamol)
- Nefopam hydrochloride
- Papaveretum
- Aspirin
Other Indications
- Lambert-Eaton myasthenic syndrome (LEMS)
- Pain
- Osteoarthritis
- Penile rehabilitation
- Erectile dysfunction
- Hyperuricaemia and Gout
- Dysphagia
- Low sexual desire in menopausal women
- Psoriasis
- Atopic dermatitis
- Multiple sclerosis
- Duchenne muscular dystrophy
- Multiple sclerosis
- Systemic Lupus Erythematosus
- Inclusion body myositis
- Systemic Lupus Erythematosus
- Duchenne muscular dystrophy
- Systemic Lupus Erythematosus
- Multiple sclerosis
- Short bowel syndrome
- Any paediatric use
- Erectile dysfunction combination therapy
- Children and young people with Epilepsy
- Diabetes Mellitus
- Interface Prescribing Policy (IPP)
- Restless Leg Syndrome
- Narcolepsy
- Menopausal disorders
- Menopausal disorders
- All
- Atopic dermatitis
- Psoriasis
- Covid-19
- Covid-19
- Covid-19
- Inflammatory bowel disease
- Ulcerative colitis - moderately to severely active
- Migraine (prevention)
- Dry eyes
- Cancer
- Diarrhoea
- Ulcerative colitis - moderately to severely active
- Non-radiographic axial spondyloarthritis
- Photoaggravated dermatoses
- Photodermatoses
- Metabolic disorders
- Insomnia in adults
- Cardiomyopathy
- Epidermolysis bullosa
- Photoaggravated dermatoses
- Psoriasis
- Psoriatic arthritis
- Photodermatoses
- Photodermatoses
- Photoaggravated dermatoses
- Catheter maintenance solutions
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dysphagia
- Prurigo nodularis
- Vitamin D deficiency and insufficiency
- Osteoporosis
- Migraine (prevention)
- Pustular psoriasis
- Mucus clearance
- Atopic dermatitis
- Alopecia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Smoking cessation
- Pain
- Homozygous familial hypercholesterolaemia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Metabolic disorders
- Concious sedation
- Premedication
- post Bariatric surgery
- Erectile dysfunction
- Parkinson's disease
- Myasthenia gravis
- Covid-19
Additional Documents
No additional documents returned.
Committee Recommendations
This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.
This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net if they wish to make a submission.